Zealand Pharma has been granted a patent for compstatin analogues with improved binding and complement-inhibiting activity compared to the original peptide. These analogues, including variants with an isoleucine residue at position 3, offer increased solubility and potential for modifications to enhance efficacy. GlobalData’s report on Zealand Pharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Zealand Pharma, Hormone-based therapies for metabolic disorders was a key innovation area identified from patents. Zealand Pharma's grant share as of May 2024 was 33%. Grant share is based on the ratio of number of grants to total number of patents.
Compstatin analogues with improved binding and complement-inhibiting activity
A recently granted patent (Publication Number: US11965039B2) discloses a series of compstatin analogues represented by specific chemical formulas. These analogues are designed to inhibit complement activation, a key component of the immune system. The compounds described in the patent have a disulphide bond between cysteine residues at specific positions within the molecule, and may optionally include lipophilic groups covalently linked to certain amino acid residues. The analogues are intended for use in pharmaceutical compositions to treat conditions related to complement activation.
The patent covers a range of compstatin analogues with variations in the amino acid sequences and structures, all aimed at inhibiting complement activation. The analogues may include lipophilic groups, and the patent also describes methods for inhibiting complement activation in subjects in need of treatment. Additionally, the patent discloses compositions containing the compstatin analogues in combination with carriers or excipients for pharmaceutical use. The detailed chemical structures and sequences provided in the patent offer a comprehensive overview of the compstatin analogues and their potential applications in therapeutic interventions targeting complement activation.
To know more about GlobalData’s detailed insights on Zealand Pharma, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
